An observational study in Severe Asthma, sponsored by Medical University of Warsaw. Completed at 1 site in Poland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-11.
Sponsored by Medical University of Warsaw · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 255 studies in Asthma with a site in Poland — 14 open to participants now, 22 under way, 7 of them phase 3. Asthma · Poland.
Among the 255 studies in Asthma with a site in Poland, this one is the 18th largest by enrollment of the 18 observational ones that give a count, is one of 19 that started in 2013, is one of 18 observational ones, and was the 179th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →14 of the 255 studies in Asthma with a site in Poland are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Poland, Argentina, France and 7 more countries
Ages 12–17
AstraZeneca · Sites in Poland, United States, Argentina and 11 more countries
Ages 6+
Kymera Therapeutics, Inc. · Sites in Poland, United States, Germany and 1 more country
Ages 18+
AstraZeneca · Sites in Poland, United States, Argentina and 4 more countries
Ages 4–11
Medical University of Warsaw · Sites in Poland
Ages up to 17
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
255 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 94 · Phase 3 114 · Phase 4 20
First in 2002; this study’s year is marked. 19 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 372 across the 236 interventional studies, 240 across the 18 observational. Of the 224 that completed or were terminated, 144 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
220 of 255 have an industry lead sponsor. The 10 most frequent:
Medical University of Warsaw is the lead sponsor of 327 studies on the registry; 88 are open to participants now.
Medical University of Warsaw has 9 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
9 of the studies in Asthma with a site in Poland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT07786870Medical University of WarsawExpression of TSLP Isoforms in Asthma | 2026-11 |
| NCT05851443Incyte CorporationA Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | 2026-11-20 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add all 9 to your calendar (.ics) → With an account.
Among the 255 studies in Asthma with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Eosinophil infiltration and degranulation in airways has been implicated in the pathology of asthma. Periostin is considered to be a marker of eosinophilic inflammation and is one of the highly expressed genes in epithelial cells and lung fibroblasts in asthma. Omalizumab is approved as add-on therapy in the treatment of severe allergic asthma. The aim of the study is to assess inflammatory biomarkers including: blood and sputum eosinophilia, periostin and IL-6 as long-term clinical outcomes of omalizumab therapy.
Anti-IgE (omalizumab) has been shown to be an effective add-on therapy for patients with allergic severe asthma. In this observational study patients aged over 18 year with uncontrolled severe persistent asthma are selected for add-on therapy with omalizumab. Patients were on high dose of ICS and had a documented history of 2-6 exacerbations requiring treatment with systemic corticosteroids ( with >15 mg/day prednisone or other medications at similar dose, for at least 3 days). The individual dose and frequency of omalizumab administration is assessed from the dosing table. Lung function tests and asthma questionnaires (ACQ, AQLQ and RQLQ) are used in the aim of assessing clinical improvement after omalizumab treatment. Induced sputum (IS) and exhaled breath condensate (EBC) are used as a simple non-invasive methods for monitoring cellular and biochemical changes in the airways. Total blood eosinophil count, IS cytology, IS and EBC periostin and IL-6 concentrations are measured. Analyses are performed at entry and after 16, 52 and 104,156 weeks of omalizumab treatment.
Severe allergic asthma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study also gives OmalizumabStudies of OmalizumabOmalizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Change in selected biomarkers in induced sputum
eosinophil count
Time frame: baseline and after 156 weeks of omalizumab treament
Change in selected biomarkers in peripheral blood
eosinophil count
Time frame: baseline and after 156 weeks of omalizumab treament
Change in selected biomarkers in induced sputum
periostin
Time frame: baseline and after 156 weeks of omalizumab treament
Change in selected biomarkers in exhaled breath condensate
periostin
Time frame: baseline and after 156 weeks of omalizumab treament
Change in selected biomarkers in induced sputum
IL-6
Time frame: baseline and after 156 weeks of omalizumab treament
Change in selected biomarkers in exhaled breath condensate
IL-6
Time frame: baseline and after 156 weeks of omalizumab treament
Change in selected biomarkers in induced sputum
eosinophils, periostin, IL-6
Time frame: baseline and after at 16,52,104 weeks of omalizumab treament
Change in selected biomarkers in exhaled breath condensate
periostin, IL-6
Time frame: baseline and after at 16, 52, 104 weeks of omalizumab treament
Change in selected biomarkers in peripheral blood
eosinophil count
Time frame: baseline and after at 16, 52, 104 weeks of omalizumab treament
Lung function tests
FEV1, FVC, FEV1/FVC
Time frame: baseline and after at 16, 52, 104, 156 weeks of treament
Plan to share: No
Ran from Apr 2013 to primary completion in Nov 2018, 67 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Warsaw →